Decision making by p53: Life, death and cancer

Cell Death and Differentiation

Volumn 10, Issue 4, 2003, Pages 431-442

  Oren, Moshe ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

AKT; Apoptosis; Beta catenin; GSK 3; p53

Indexed keywords

BETA CATENIN; DNA; GLYCOGEN SYNTHASE KINASE 3BETA; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; REGULATOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

APOPTOSIS; BIOCHEMISTRY; CANCER INHIBITION; CELL AGING; CELL DEATH; CELL FATE; CELL GROWTH; CELL TRANSFORMATION; DECISION MAKING; DNA REPAIR; GENE REPRESSION; GENE TARGETING; GENETIC REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STEADY STATE; STRESS; TRANSACTIVATION;

ANIMALS; APOPTOSIS; BETA CATENIN; CELL TRANSFORMATION, NEOPLASTIC; CYTOSKELETAL PROTEINS; GENE EXPRESSION REGULATION; GENES, REGULATOR; HUMANS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0038075338     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401183     Document Type: Review

References (123)

1. Oren M and Rotter V (1999) Introduction: p53-the first twenty years. Cell Mol. Life Sci. 55: 9-11
2. Alarcon-Vargas D and Ronai Z (2002) p53-Mdm2 - the affair that never ends. Carcinogenesis 23: 541-547
3. Ashcroft M, Taya Y and Vousden KH (2000) Stress signals utilize multiple pathways to stabilize p53. Mol. Cell Biol. 20: 3224-3233
4. Bargonetti J and Manfredi JJ (2002) Multiple roles of the tumor-suppressor p53. Curr. Opin. Oncol. 14: 86-91
5. Hickman ES, Moroni MC and Helin K (2002) The role of p53 and pRB in apoptosis and cancer. Curr. Opin. Genet. Dev. 12: 60-66
6. Michael D and Oren M (2002) The p53 and Mdm2 families in cancer. Curr. Opin. Genet. Dev. 12: 53-59
7. Sears RC and Nevins JR (2002) Signaling networks that link cell proliferation and cell fate. J. Biol. Chem. 277: 11617-11620
8. Shen Y and White E (2001) p53-dependent apoptosis pathways. Adv. Cancer Res. 82: 55-84
9. Vogelstein B, Lane D and Levine AJ (2000) Surfing the p53 network. Nature 408: 307-310
10. Woods DB and Vousden KH (2001) Regulation of p53 function. Exp. Cell Res. 264: 56-66
11. Kaeser MD and Iggo RD (2002) Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc. Natl. Acad. Sci. USA 99: 95-100
12. Daujat S, Neel H and Piette J (2001) MDM2: life without p53. Trends Genet. 17: 459-464
13. Deb SP (2002) Function and dysfunction of the human oncoprotein MDM2. Front Bio. Sci. 7: d235-243
14. Momand J, Wu HH and Dasgupta G (2000) MDM2-master regulator of the p53 tumor-suppressor protein. Gene. 242: 15-29
15. Asher G, Lotem J, Kama R, Sachs L and Shaul Y (2002) NQO1 stabilizes p53 through a distinct pathway. Proc. Natl. Acad. Sci. USA 99: 3099-3104
16. Benetti R, Del Sal G, Monte M, Paroni G, Brancolini C and Schneider C (2001) The death substrate Gas2 binds m-calpain and increases susceptibility to p53-dependent apoptosis. EMBO J. 20: 2702-2714
17. Fuchs SY, Adler V, Buschmann T, Yin Z, Wu X, Jones SN and Ronai Z (1998) JNK targets p53 ubiquitination and degradation in nonstressed cells. Genes Dev. 12: 2658-2663
18. Kubbutat MH and Vousden KH (1997) Proteolytic cleavage of human p53 by calpain: a potential regulator of protein stability. Mol. Cell Biol. 17: 460-468
19. Weitzman JB, Fiette, L, Matsuo K and Yaniv M (2000) JunD protects cells from p53-dependent senescence and apoptosis. Mol. Cell 6: 1109-1119
20. Tergaonkar V, Pando M, Vafa O, Wahl G and Verma I (2002) p53 stabilization is decreased upon NFkappaB activation. A role for NFkappaB in acquisition of resistance to chemotherapy. Cancer Cell 1: 493-503
21. Ryan KM, Ernst MK, Rice NR and Vousden KH (2000) Role of NF-kappaB in p53-mediated programmed cell death. Nature 404: 892-897
22. Chao C, Saito S, Kang J, Anderson CW, Appella E and Xu Y (2000) p53 transcriptional activity is essential for p53-dependent apoptosis following DNA damage. EMBO J. 19: 4967-4975
23. Jimenez GS, Nister M, Stommel JM, Beeche M, Barcarse EA, Zhang XQ, O'Gorman S and Wahl GM (2000) A transactivation-deficient mouse model provides insights into Trp53 regulation and function. Nat. Genet. 26: 37-43
24. Friedlander P, Haupt Y, Prives C and Oren M (1996) A mutant p53 that discriminates between p53 responsive genes cannot induce apoptosis. Mol. Cell Biol. 16: 4961-4971
25. Ludwig RL, Bates S and Vousden KH (1996) Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol. Cell. Biol. 16: 4952-4960
26. Lohrum M and Scheidtmann KH (1996) Differential effects of phosphorylation of rat p53 on transactivation of promoters derived from different p53 responsive genes. Oncogene 13: 2527-2539
27. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y and Taya Y (2000) p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 102: 849-862
28. Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, Ambrosino C, Sauter G, Nebreda AR, Anderson CW, Kallioniemi A, Fornace Jr AJ and Appella E (2002) Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat. Genet. 31: 210-215
29. Chehab NH, Malikzay A, Appel M and Halazonetis TD (2000) Chk2/hCds1 functions as a DNA damage checkpoint in G1 by stabilizing p53. Genes Dev. 14: 278-288
30. Jack MT, Woo RA, Hirao A, Cheung A, Mak TW and Lee PW (2002) Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response. Proc. Natl. Acad. Sci. USA 99: 9825-9829
31. Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole PA, Fontemaggi G, Fanciulli M, Schiltz L, Blandino G, Balsano C and Levrero M (2002) DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol. Cell 9: 175-186
32. Wang Y and Prives C (1995) Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. Nature 376: 88-91
33. Samuels-Lev Y, O'Connor DJ, Bergamaschi D, Trigiante G, Hsieh JK, Zhong S, Campargue I, Naumovski L, Crook T and Lu X (2001) ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cell 8: 781-794
34. Shikama N, Lee CW, France S, Delavaine L, Lyon J, Krstic-Demonacos M and La Thangue NB (1999) A novel cofactor for p300 that regulates the p53 response. Mol. Cell 4: 365-376
35. Frade R, Balbo M and Barel M (2000) RB18A, whose gene is localized on chromosome 17q12-q21.1, regulates in vivo p53 transactivating activity. Cancer Res. 60: 6585-6589
36. Rozenfeld-Granot G, Krishnamurthy J, Kannan K, Toren A, Amariglio N, Givol D and Rechavi G (2002) A positive feedback mechanism in the transcriptional activation of Apaf-1 by p53 and the coactivator Zac-1. Oncogene 21: 1469-1476
37. Szak ST, Mays D and Pietenpol JA (2001) Kinetics of p53 binding to promoter sites in vivo. Mol. Cell Biol. 21: 3375-3386
38. Contente A, Dittmer A, Koch MC, Roth J and Dobbelstein M (2002) A polymorphic microsatellite that mediates induction of PIG3 by p53. Nat. Genet. 30: 315-320
39. Wu X and Levine AJ (1994) p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA 91: 3602-3606
40. Hsieh JK, Yap D, O'Connor DJ, Fogal V, Fallis L, Chan F, Zhong S and Lu X (2002) Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage. Mol. Cell Biol. 22: 78-93
41. Rogoff HA, Pickering MT, Debatis ME, Jones S and Kowalik TF (2002) E2F1 induces phosphorylation of p53 that is coincident with p53 accumulation and apoptosis. Mol. Cell Biol. 22: 5308-5318
42. Moroni MC, Hickman ES, Denchi EL, Caprara G, Colli E, Cecconi F, Muller H and Helin K (2001) Apaf-1 is a transcriptional target for E2F and p53. Nat. Cell Biol. 3: 552-558
43. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F and Jacks T (2002) p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416: 560-564
44. Maheswaran S, Englert C, Bennett P, Heinrich G and Haber DA (1995) The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. Genes Dev. 9: 2143-2156
45. MacLachlan TK, Takimoto R and El-Deiry WS (2002) BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. Mol. Cell Biol. 22: 4280-4292
46. Dumaz N and Meek DW (1999) Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J. 18: 7002-7010
47. Lambert PF, Kashanchi F, Radonovich MF, Shiekhattar R and Brady JN (1998) Phosphorylation of p53 serine 15 increases interaction with CBP. J. Biol. Chem. 273: 33048-33053
48. Wang T, Kobayashi T, Takimoto R, Denes AE, Snyder EL, el-Deiry WS and Brachmann RK (2001) hADA3 is required for p53 activity. EMBO J. 20: 6404-6413
49. Ginsberg D, Mechta F, Yaniv M and Oren M (1991) Wild-type p53 can down-modulate the activity of various promoters. Proc. Natl. Acad. Sci. USA 88: 9979-9983
50. Zilfou JT, Hoffman WH, Sank M, George DL and Murphy M (2001) The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation. Mol. Cell Biol. 21: 3974-3985
51. Venot C, Maratrat M, Dureuil C, Conseiller E, Bracco L and Debussche L (1998) The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J. 17: 4668-4679
52. Sabbatini P, Chiou SK, Rao L and White E (1995) Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19 K protein. Mol. Cell Biol. 15: 1060-1070
53. Shen YQ and Shenk T (1994) Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular bcl-2 protein. Proc. Natl. Acad. Sci. USA 91: 8940-8944
54. Ryan KM and Vousden KH (1998) Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest. Mol. Cell Biol. 18: 3692-3698
55. Haldar S, Negrini M, Monne M, Sabbioni S and Croce CM (1994) Downregulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 54: 2095-2097
56. Miyashita T, Harigai M, Hanada M and Reed JC (1994) Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 54: 3131-3135
57. Sugars KL, Budhram-Mahadeo V, Packham G and Latchman DS (2001) A minimal Bcl-x promoter is activated by Brn-3a and repressed by p53. Nucleic Acids Res. 29: 4530-4540
58. Hoffman WH, Biade S, Zilfou JT, Chen J and Murphy M (2002) Transcriptional repression of the anti apoptotic survivin gene by wild type p53. J. Biol. Chem. 277: 3247-3257
59. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB and Liu S (2002) Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21: 2613-2622
60. Caelles C, Helmberg A and Karin M (1994) p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370: 220-223
61. Haupt Y, Rowan S, Shaulian E, Vousden KH and Oren M (1995) Induction of apoptosis in HeLa cells by trans-activation-deficient p53. Gene Dev. 9: 2170-2183
62. Wagner AJ, Kokontis JM and Hay N (1994) Myc-mediated apoptosis requiRes wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21(waf1/cip1). Gene Develop. 8: 2817-2830
63. Baptiste N, Friedlander P, Chen X and Prives C (2002) The proline-rich domain of p53 is required for cooperation with anti neoplastic agents to promote apoptosis of tumor cells. Oncogene 21: 9-21
64. Matas D, Sigal A, Stambolsky P, Milyavsky M, Weisz L, Schwartz D, Goldfinger N and Rotter V (2001) Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. EMBO J. 20: 4163-4172
65. Bennett M, Macdonald K, Chan SW, Luzio JP, Simari R and Weissberg P (1998) Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis [see comments]. Science 282: 290-293
66. Schuler M, Bossy-Wetzel E, Goldstein JC, Fitzgerald P and Green DR (2000) p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. J. Biol. Chem. 275: 7337-7342
67. Ding HF and Fisher DE (2001) p53, caspase 8, and regulation of apoptosis after ionizing radiation. J. Pediatr. Hematol. Oncol. 23: 185-188
68. Moll UM and Zaika A (2001) Nuclear and mitochondrial apoptotic pathways of p53. FEBS Lett. 493: 65-69
69. Regula KM and Kirshenbaum LA (2001) p53 activates the mitochondrial death pathway and apoptosis of ventricular myocytes independent of de novo gene transcription. J. Mol. Cell Cardiol. 33: 1435-1445
70. Vikhanskaya F, D'Incalci M and Broggini M (1995) Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes. Int. J. Cancer 61: 397-401
71. Malcomson RDG, Oren M, Wyllie AH and Harrison DJ (1995) P53-independent death and p53-induced protection against apoptosis in fibroblasts treated with chemotherapeutic drugs. Br. J. Cancer 72: 952-957
72. Lassus P, Bertrand C, Zugasti O, Chambon JP, Soussi T, Mathieu-Mahul D and Hibner U (1999) Antiapoptotic activity of p53 maps to the COOH-terminal domain and is retained in a highly oncogenic natural mutant. Oncogene 18: 4699-4709
73. McKay BC, Becerril C and Ljungman M (2001) P53 plays a protective role against UV- and cisplatin-induced apoptosis in transcription-coupled repair proficient fibroblasts. Oncogene 20: 6805-6808
74. Gorospe M, Cirielli C, Wang XT, Seth P, Capogrossi MC and Holbrook NJ (1997) p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. Oncogene 14: 929-935
75. Bissonnette N and Hunting DJ (1998) p21-induced cycle arrest in G1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage. Oncogene 16: 3461-3469
76. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW and Vogelstein B (1998) Requirement for p53 and p21 to Sustain G2 arrest after DNA damage. Science 282: 1497-1501
77. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW and Vogelstein B (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104: 263-269
78. Mariette X, Sibilia J, Roux S, Meignin V and Janin A (2002) A new defensive mechanism to prevent apoptosis in salivary ductal cells from patients with Sjogren's syndrome: over-expression of p53 and p21. Rheumatology (Oxford) 41: 96-99
79. Polyak K, Waldman T, He TC, Kinzler KW and Vogelstein B (1996) Genetic determinants of p53-induced apoptosis and growth arrest. Gene Develop. 10: 1945-1952
80. Wang Y, Blandino G and Givol D (1999) Induced p21waf expression in H1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin. Oncogene 18: 2643-2649
81. Roninson IB (2002) Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett. 179: 1-14
82. Shaulian E, Schreiber M, Piu F, Beeche M, Wagner EF and Karin M (2000) The mammalian UV response: c-Jun induction is required for exit from p53-imposed growth arrest. Cell 103: 897-907
83. Li Y, Dowbenko D and Lasky LA (2002) AKT/PKB phosphorylation of p21Cip1/WAF1 enhances protein stability of p21Cip1/WAF1 and promotes cell survival. J. Biol. Chem. 277:11352-11361
84. Rossig L, Badorff C, Holzmann Y, Zeiher AM and Dimmeler S (2002) Glycogen synthase kinase-3 couples AKT-dependent signaling to the regulation of p21Cip1 degradation. J. Biol. Chem. 277: 9684-9689
85. Meng RD, McDonald III ER, Sheikh MS, Fornace Jr AJ and El-Deiry WS (2000) The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol. Ther. 1: 130-144
86. Fang L, Li G, Liu G, Lee SW and Aaronson SA (2001) p53 induction of heparin-binding EGF-like growth factor counteracts p53 growth suppression through activation of MAPK and PI3K/Akt signaling cascades. EMBO J. 20: 1931-1939
87. Peifer M and Polakis P (2000) Wnt signaling in oncogenesis and embryogenesis - a look outside the nucleus. Science 287: 1606-1609
88. Brantjes H, Barker N, van EJ and Clevers H (2002) TCF: Lady Justice casting the final verdict on the outcome of Wnt signalling. Biol. Chem. 383: 255-261
89. Polakis P (2000) Wnt signaling and cancer. Genes Dev. 14: 1837-1851
90. Damalas A, Ben-Ze'ev A, Simcha I, Shtutman M, Leal JF, Zhurinsky J, Geiger B and Oren M (1999) Excess beta-catenin promotes accumulation of transcriptionally active p53. EMBO J. 18: 3054-3063
91. Lowe SW (1999) Activation of p53 by oncogenes. Endocr. Relat. Cancer 6: 45-48
92. Sherr CJ and Weber JD (2000) The ARF/p53 pathway. Curr. Opin. Genet. Dev. 10: 94-99
93. Russell JL, Powers JT, Rounbehler RJ, Rogers PM, Conti CJ and Johnson DG (2002) ARF differentially modulates apoptosis induced by E2F1 and Myc. Mol. Cell Biol. 22: 1360-1368
94. Damalas A, Kahan S, Shtutman M, Ben-Ze'ev A and Oren M (2001) Deregulated beta-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation. EMBO J. 20: 4912-4922
95. Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB and Herman JG (2000) Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res. 60: 129-133
96. Tolbert D, Lu X, Yin C, Tantama M and Van Dyke T (2002) p19(ARF) is dispensable for oncogenic stress-induced p53-mediated apoptosis and tumor suppression in vivo. Mol. Cell Biol. 22: 370-377
97. Su F, Overholtzer M, Besser D and Levine AJ (2002) WISP-1 attenuates p53-mediated apoptosis in response to DNA damage through activation of the Akt kinase. Genes Dev. 16: 46-57
98. Liu J, Stevens J, Rote CA, Yost HJ, Hu Y, Neufeld KL, White RL and Matsunami N (2001) Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. Mol. Cell 7: 927-936
99. Matsuzawa SI and Reed JC (2001) Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol. Cell 7: 915-926
100. Sadot E, Geiger B, Oren M and Ben-Ze'ev A (2001) Downregulation of beta-catenin by activated p53. Mol. Cell Biol. 21: 6768-6781
101. Yang A, Kaghad M, Caput D and McKeon F (2002) On the shoulders of giants: p63, p73 and the rise of p53. Trends Genet. 18: 90-95
102. Patturajan M, Nomoto S, Sommer M, Fomenkov A, Hibi K, Zangen R, Poliak N, Califano J, Trink B, Ratovitski E and Sidransky D (2002) DeltaNp63 induces beta-catenin nuclear accumulation and signaling. Cancer Cell 1: 369-379
103. Nicholson KM and Anderson NG (2002) The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 14: 381-395
104. Brazil DP and Hemmings BA (2001) Ten years of protein kinase B signalling: a hard Akt to follow. Trends Bio. Chem. Sci. 26: 657-664
105. Ashcroft M, Ludwig RL, Woods DB, Copeland TD, Weber HO, MacRae EJ and Vousden KH (2002) Phosphorylation of HDM2 by Akt. Oncogene 21: 1955-1962
106. Gottlieb TM, Leal JF, Seger R, Taya Y and Oren M. (2002) Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene 21: 1299-1303
107. Mayo LD and Donner DB (2001) A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. USA 98: 11598-11603
108. Ogawara Y, Kishishita. S, Obata T, Isazawa Y, Suzuki T, Tanaka K, Masuyama N and Gotoh Y (2002) Akt enhances Mdm2-mediated ubiquitination and degradation of p53. J. Biol. Chem. 277: 21843-21850
109. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B and Hung MC (2001) HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 3: 973-982
110. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S and Mak TW (2001) Regulation of PTEN Transcription by p53. Mol. Cell 8: 317-325
111. Singh B, Reddy PG, Goberdhan A, Walsh C, Dao S, Ngai I, Chou TC, Levine AJ, Rao PH and Stoffel A (2002) p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. Genes Dev. 16: 984-993
112. Weston CR and Davis RJ (2001) Signal transduction: signaling specificity - a complex affair. Science 292: 2439-2440
113. Watcharasit P, Bijur GN, Zmijewski JW, Song L, Zmijewska A, Chen X, Johnson GV and Jope RS (2002) Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage. Proc. Natl. Acad. Sci. USA 99: 7951-7955
114. Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoel MJ, Bertrand F, Cherqui G, Perret C and Capeau J (2001) Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 20: 252-259
115. Fukumoto S, Hsieh CM, Maemura K, Layne MD, Yet SF, Lee KH, Matsui T, Rosenzweig A, Taylor WG, Rubin JS, Perrella MA and Lee ME (2001) Akt participation in the Wnt signaling pathway through Dishevelled. J. Biol. Chem. 276: 17479-17483
116. Monick MM, Carter AB, Robeff PK, Flaherty DM, Peterson MW and Hunninghake GW (2001) Lipopolysaccharide activates Akt in human alveolar macrophages resulting in nuclear accumulation and transcriptional activity of beta-catenin. J. Immunol. 166: 4713-4720
117. Satyamoorthy K, Li G, Vaidya B, Patel D and Herlyn M (2001) Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and beta-catenin pathways. Cancer Res. 61: 7318-7324
118. Persad S, Troussard AA, McPhee TR, Mulholland DJ and Dedhar S (2001) Tumor-suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. J. Cell Biol. 153: 1161-1174
119. Sharma M, Chuang WW and Sun Z (2002) Phosphatidylinosital 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta - catenin accumulation. J. Biol. Chem, 277: 30935-30941
120. Pap M and Cooper GM (1998) Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-Kinase/Akt cell survival pathway. J. Biol. Chem. 273: 19929-19932
121. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM and Lowe SW (2002) Dissecting p53 tumor-suppressor functions in vivo. Cancer Cell 1: 289-298
122. Symonds H, Krall L, Remington L, Saenzrobles M, Lowe S, Jacks T and Vandyke T (1994) p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 71: 103-711
123. Fazeli A, Steen RG, Dickinson SL, Bautista D, Dietrich WF, Bronson RT, Bresalier RS, Lander ES, Costa J and Weinberg RA (1997) Effects of p53 mutations on apoptosis in mouse intestinal and human colonic adenomas. Proc. Natl. Acad. Sci. USA 94: 10199-10204